Every 424B that Jade Biosciences, Inc. (JBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow JBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JBIO filings page.
Jade Biosciences is offering 10,000,000 shares of its common stock at $15.00 per share in a registered primary offering. The prospectus supplement states gross proceeds of $150,000,000, underwriting discounts of $9,000,000 and estimated net proceeds to the company of approximately $140.3 million (or approximately $161.5 million if the underwriters fully exercise a 30-day option to purchase an additional 1,500,000 shares). The company reports 49,345,967 shares outstanding as of March 31, 2026 and a net tangible book value of $6.00 per share as of that date; dilution to new investors at the offering price is stated as $7.64 per share. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes.
Jade Biosciences, Inc. is offering shares of its common stock and pre-funded warrants in a registered offering under a Form S-3 shelf prospectus supplement dated June 3, 2026. The prospectus supplement describes primary sales of common stock and pre-funded warrants, with underwriting and customary lock-up arrangements.
The company reports 49,345,967 shares of common stock outstanding as of March 31, 2026, a reported net tangible book value of $296.5 million (approximately $6.00 per share) as of that date, and states $200 million of shares remain available under an existing Sales Agreement with Jefferies. The supplement discloses interim Phase 1 JADE101 data and plans for Phase 2/Phase 3 development, and includes customary risk factors, use-of-proceeds, dilution analysis, and tax discussion.
Jade Biosciences, Inc. is registering 39,542,339 shares of Common Stock for resale by selling stockholders under a shelf prospectus. The Resale Shares include October 2025 PIPE shares and pre-funded warrants, December 2025 PIPE shares, shares issued in connection with Pre-Merger Financing, and shares issuable upon conversion of Series A Preferred Stock.
The company states it will not receive proceeds from resale by the selling stockholders, but will receive nominal cash exercise prices if certain pre-funded warrants are exercised for cash. The registration satisfies contractual registration rights under April, October and December 2025 registration rights agreements.
Jade Biosciences, Inc. (JBIO) filed a prospectus supplement to update its Form S-1 with information from its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company reported a net loss of $40.4 million for the quarter and used $24.1 million of cash in operations. Cash and cash equivalents were $55.1 million and investments were $256.2 million, totaling $311.3 million as of March 31, 2026. Shares outstanding were 49,359,875 as of May 1, 2026. The prospectus supplement also discloses an Open Market Sales Agreement entered May 7, 2026, under which the company may sell up to $200.0 million of common stock in at‑the‑market offerings (the company has not sold any shares under that agreement to date).
Jade Biosciences, Inc. files a prospectus supplement to its Form S-1 to update the offering document with information from its Form 10-Q for the quarter ended March 31, 2026. The supplement relates to Common Stock offered by selling stockholders and references a recent May 7, 2026 Form 10-Q.
The 10-Q discloses cash and cash equivalents of $55.1 million, investments of $256.2 million (totaling $311.3 million), a net loss of $40.4 million for the three months ended March 31, 2026, and 49,359,875 shares outstanding as of May 1, 2026. The supplement updates risk and operational disclosures and attaches the quarterly financial statements.
Jade Biosciences, Inc. files a prospectus supplement to update its offering materials and incorporates key disclosures from its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The prospectus supplement states the company’s common stock trades on Nasdaq under the symbol JBIO, with a last reported sale price of $13.88 per share on March 5, 2026. The Form 10-K reports 49,316,287 shares outstanding as of February 28, 2026 and an aggregate market value held by non-affiliates of approximately $289.4 million as of June 30, 2025. The Form 10-K describes Jade’s pipeline (lead candidate JADE101 in Phase 1 for IgA nephropathy, planned Phase 2 start in mid-2026), JADE201 plans (Phase 1 planned in Q2 2026), collaboration and license terms with Paragon and third-party manufacturing arrangements.
Jade Biosciences, Inc. files a prospectus supplement to the S-1 registering common stock for resale by a selling stockholder.
The supplement incorporates by reference the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The filing discloses 49,316,287 shares outstanding as of February 28, 2026 and a last reported Nasdaq sale price of $13.88 per share on March 5, 2026.